Silence Therapeutics PLC Litigation Update (Portugal and US) (5353J)
April 03 2018 - 1:01AM
UK Regulatory
TIDMSLN
RNS Number : 5353J
Silence Therapeutics PLC
03 April 2018
Litigation Update (Portugal and US)
London, 3(rd) April 2018
Silence Therapeutics plc, AIM:SLN ("the Company") a leader in
the discovery, delivery, and development of novel RNA therapeutics
for the treatment of serious diseases with unmet medical need,
announces that, through Silence Therapeutics Gmbh (together
"Silence"), it has yesterday brought patent infringement
proceedings in Portugal against Alnylam's Patisiran product, and
that on March 29(th) Alnylam Pharmaceuticals Inc. ("Alnylam") filed
a Declaratory Judgement (DJ) against Silence Therapeutics plc and
Silence Therapeutics Gmbh.
Regarding Portugal, Silence has previously stated that it is
committed to defending its Intellectual Property (IP) and to secure
the appropriate value for this IP it will act to enforce its patent
estate as necessary. The next phase in the Portuguese legal process
is that the Court will serve the claim on the defendant. The claim
asks the Court to determine whether Patisiran infringes the Silence
patent EP 1857547.
Regarding the US, Alnylam filed the Declaratory Judgment action
in the U.S. federal district court in Boston, Massachusetts. The
action seeks a finding of non-infringement of certain Silence
patents. Silence's most recently-issued U.S. patents, such as those
identified in Silence's updates dated August 15, 2017, October 11,
2017, and October 18, 2017, are not named in the lawsuit. The
complaint has not yet been served on Silence. More information on
the lawsuit can be found on the court's docket, at case number
mad-1-18-cv-10613.
Ali Mortazavi, Chief Executive Officer of Silence Therapeutics
plc, commented:
"We reiterate that we will defend the Silence patent estate
where we consider third parties to be infringing the company's
patent rights. As such, in Portugal we consider this process to be
important in recognizing the contribution Silence has made to this
field. Furthermore, we see Alnylam's filing of a DJ as an
acknowledgment of the significance of our patent position."
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20 3457
Ali Mortazavi, Chief Executive 6900
Officer
David Ellam, Chief Financial
Officer
Peel Hunt LLP (Nominated Tel: +44 (0)20 7418
Adviser and Broker) 8900
James Steel/Oliver Jackson
Media Enquiries:
Optimum Strategic Communications Tel: +44 (0) 20 3714
Mary Clark/ Eva Haas/Hollie 1788
Vile
silence@optimumcomms.com
IR Enquires - US Tel: +1 (212) 213
Burns McClellan 0006
John Grimaldi
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by
harnessing the body's natural mechanism of RNA interference, or
RNAi, within its cells. Our proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-causing proteins. Using our enabling delivery
systems, we have achieved an additional level of specificity by
delivering our therapeutic RNA molecules exclusively to target
cells. Silence's proprietary RNA chemistries and delivery systems
are designed to improve the stability of our molecules and enhance
effective delivery to target cells, providing a powerful modular
technology well suited to tackle life-threatening diseases. For
more information, please visit:
http://www.silence-therapeutics.com/
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCKLLFBVZFXBBV
(END) Dow Jones Newswires
April 03, 2018 02:01 ET (06:01 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024